⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22495741 | 0.86 | ACHE (0.42) | — | |
| Methylcyclopentane SCHEMBL11593657 | 0.83 | CA12 (0.39) | — | |
| SCHEMBL14764831 | 0.81 | CA12 (0.42) | — | |
| SCHEMBL13973741 | 0.78 | LMNA (0.31) | — | |
| SCHEMBL28809825 | 0.77 | — | — | |
| SCHEMBL8658250 | 0.73 | — | — | |
| SCHEMBL1182 | 0.73 | — | — | |
| Propylene Oxide SCHEMBL29216598 | 0.72 | — | — | |
| SCHEMBL8600626 | 0.72 | EPHX1 (0.41) | — | |
| SCHEMBL9992835 | 0.69 | SMN1; SMN2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119487021-A | Heterocyclic derivatives as inhibitors of mitogen-activated protein kinase (MEK) | 内斯特治疗公司 | 2025-02-18 | — | — | CN | disclosed |
| US-11884649-B2 | IRE1α inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4243815-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116583276-A | IRE1 alpha inhibitors and uses thereof | 加利福尼亚大学董事会 | 2023-08-11 | — | — | CN | disclosed |
| CN-116462674-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116444510-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-111108102-B | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | disclosed |
| WO-2022104151-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20220153723-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | UNIVERSITY OF WASHINGTON | 2022-05-19 | — | — | US | disclosed |
| US-20180290984-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017066428-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| CN-106478651-A | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2017-03-08 | — | — | CN | disclosed |
| WO-2016022460-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| CN-103209964-A | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE DEUTSCHLAND | 2013-07-17 | — | — | CN | disclosed |
| CN-102858754-A | RAF inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC | 2013-01-02 | — | — | CN | disclosed |
| EP-2475667-A1 | INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| CN-102131771-A | Compositions and methods for preparing and using same | ARDEA BIOSCIENCES INC | 2011-07-20 | — | — | CN | disclosed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |